Results 61 to 70 of about 10,317 (226)

Sweet taste loss in myasthenia gravis: more than a coincidence? [PDF]

open access: yes, 2014
Sweet dysgeusia, a rare taste disorder, may be encountered in severe anti-acetylcholine receptor antibody (AChRAb)-myasthenia gravis (MG). A 42 year-old man reported progressive loss of sweet taste evolving for almost 10 weeks, revealing an AChRAb ...
Chabwine, J.N.   +4 more
core   +5 more sources

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

open access: yesInternal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie   +14 more
wiley   +1 more source

Effects of Meal Consumption on Isotonic Lingual Endurance in Healthy Adults: A Multi‐Institutional Study

open access: yesJournal of Oral Rehabilitation, EarlyView.
Isotonic tongue endurance was measured pre‐ and post‐meal using the Iowa Oral Performance Instrument (IOPI) in healthy younger (18–35 years) and older (≥ 65 years) adults. Older adults demonstrated greater isotonic endurance and longer mealtimes, with no sex differences in endurance.
Yvette M. McCoy   +8 more
wiley   +1 more source

Disfagia e Disartria. Forma Invulgar de Apresentação da Miastenia Gravis [PDF]

open access: yes, 2007
Myasthenia Gravis is an autoimmune disorder that generally presents with ocular symptoms, specially diplopia and ptosis. Dysphagia may be a manifestation of the generalised type of the disease, but rarely is its presenting feature. The authors describe a
Alcântara, J   +5 more
core  

Representation, medical examination, and the effectiveness of underwriting: Evidence from a life and health insurance company

open access: yesRisk Management and Insurance Review, EarlyView.
Abstract This study examines whether underwriting methods—representation, medical examination, extra premiums, and coverage—effectively mitigate adverse selection using data from an insurance company. Regarding representation, we focus on statements disclosing pre‐existing medical conditions.
Chia‐Ling Ho   +3 more
wiley   +1 more source

The evaluation of approaches to the treatment of myasthenia gravis.

open access: yesMedičnì Perspektivi, 2019
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus   +4 more
doaj   +1 more source

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

open access: yes, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab   +3 more
wiley   +1 more source

An update on myasthenia gravis [PDF]

open access: yes, 2000
Myasthenia gravis (MG) is an autoimmune disease characterised by autoantibodies against acetylcholine receptors at neuromuscular junctions, resulting in defective neuromuscular transmission.
Chan, KH, Ho, SL
core  

Class A drug abuse: an ophthalmologist's problem? [PDF]

open access: yes, 2005
[First Paragraph] The 2002/3 British Crime Survey reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year.
Firth, A.Y.
core   +1 more source

Home - About - Disclaimer - Privacy